Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good morning Bobbler.
A very quick look through your excellent link and will spend a couple of hour more looking at more closely. I note GSK compound in there too.
I will have a look at their CHK1 in combo patent later. Extremely valuable would hasten to add as Royaties would become payable on its use. Kerching kerching springs to mind.
The monetary value I have very little idea but a guess far more lucrative than Momo.
Royalties to Sareum of 2.75% of total sales not to be sneezed at and not forgetting the increased lifespan and quality of life to the poor buggers who may benefit, that have a cancer, which at present has poor prognosis.
Regards
Enjoy, sounds like u have deserved it !
Good morning Blastoid. Yes it is morning and just finished a 12 hr nightshift. Last one of 3 weeks.
A couple of cases of beer, so should see me through the day, Nice piece of beef from the butchers will sear and place in oven to slow cook. Roast spuds and veggies.
Although we have had very little development news with SRA737 Sierra clearly have progressed pre clinical in combination studies.
We are the only CHK1 left I am led to believe. The important aspect where it comes into its own is in combo especially where resistance to PARP is encountered and the dreaded DNA damage repair. Similar i believe applies to PD1. CHK1 basically inhibits new cancer cell growth by blocking the P53 pathway causing cell death. On its own not effective in killing cells which exist that have no programmed cell death. Hence PD1, PARP and low dose gemcitibine ideal combo partners, Low dose gemcitibine important as toxicity is too high when used with higher dosages of Gemcitibine.
in SCLC you are looking at 10 out of 10 reduction of tumour growth where 8 remained tumour free 39 days later. This in mice model.
GSK must be rubbing their hands. Sierra get their finger out we will all be rubbing ours too.
It will take a little while to go into clinical but i forecast some outstanding results from Sierra. As to when I aint got a scooby.
Regards
Fascinating developments no doubt going on behind the scenes. 737 is worth too much to be mothballed any further ! One thing i have to pick SOG on: beer o clock ? Its breakfast time surely assuming youre in the UK !
Morning SOG. Below link details US patent application made by Sierra in relation to SRA737 and Parpi
https://patents.justia.com/patent/20210077499
You are welcome BB.
My opinion for what it is worth is that GSK will push through rapid development maybe even fast track an SRA737 combo for treatment of HGSOC into clinical trials.
Chk1, gemcitibine and PARP in combo is way above anything else we know of at the moment, (oddly on their own or any two out of 3 show very little effect) I believe there has already been a patent grant for SRA737 gemcitibine and PARP inhibitor. The link were posted a little while ago by a decent individual on here.
If GSK want to corner the HGSOC and also SCLC/NSCLC market they are 'if' and I see no reason as to why they would dismiss the addition of a checkpoint kinase inhibitor to maximise the efficacy of their own inhibitors, then they are going the right way about it.
Sierra have the ability to maximise potential of that we can rest assured. Now time to pull their finger out as virtually sat on it for past 3 years.
Regards and beer oclock for me.
Also worth a read
http://www.sareum.com/news/press-releases-and-news/2020/update-sra737-licensing-agreement/
http://www.sareum.com/news/press-releases-and-news/2021/sra737-update/
http://www.sareum.com/news/press-releases-and-news/2021/reference-sra737-timeline-cantor-conference/
Thank you, SOG
BB. Yes looks like we differ in our opinions.
No Good GSK approaching CPF as agreement is between Sierra Oncology and CPF. I have not looked at the license agreement in years. If there were a problem with on licensing, prior consent could and may have already been granted.
agrrements are made to protect the interests of the original parties who were in agreement. One side cannot unilaterally change any terms of the agreement without the consent of the other party. The milestone reduction was agreed by both parties so things can change. There was much talk when Sierra Oncology ( formerly Pronai Therapeutics ) took on the license and perhaps who they could on licence to. However, it is such that Sierra oncology cannot do just as they like with the licence agreement. The only realistic way it would return to the CPF is by default. Sierra have well delayed development but as yet not to justify costly legal action by both parties. No one wants or will benefit from that and all including the compound become tarnished.
My belief is development of SRA737 will gather rapid pace not to sell on but to use in combination with GSK inhibitors ie PARP and PD1. With a little understanding of the research carried out and the workings of the compounds themselves I am sure you are aware of the massive advantages in retaining the CHK1 inhibitor.
I have not been here long and just my view of the situation
If you care to take a look at the RNS around March 2020 you will see the following paragraph
'SRA737 was discovered and initially developed by scientists at ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 is licensed to Nasdaq-listed Sierra Oncology Inc. (“Sierra”) and has demonstrated positive safety and efficacy in combination with low-dose gemcitabine from a Phase 1/2 clinical development programme supporting standalone development in anogenital cancer. This programme is ongoing, with Sierra seeking to on-license SRA737 for further development.'
Note the 'Sierra is seeking to on-license SRA737 for further development'
ful RNS link is here
http://www.sareum.com/news/press-releases-and-news/2020/new-sra737-combinations-cancer/
Regards
Keep digging WIP LOL.
From what I saw 3 weeks ago, I’d say it was a given the Sierra deal would go through today.
As for SRA737, I’m still digging when I can. But so far, things look promising. Very. GSK know the potential value of Chk1. They bought Jemper in 2019, a PD-L1, so why not add the only available Chk1 to your portfolio? Especially when gemcitabine is now generic. It’s what Triparna Sen raved about.
Next, any potential internal links with Zentalis.
Well, it’s clear from the posts on here that there could be some different outcomes from here depending upon what GsK wants to do. But hopefully any of those will have a happy ending for Sareum. For myself, I’m just pondering how long it will take for the situation to become clear.
Bill
Thanks Bill. So probably that is a good news for SAR.
All of the agenda items were agreed. So, the GSK deal went through unobstructed.
Bill.
So what is the outcome of SIERRA shareholder meeting. It seems when I click the link it is syaing the meeting is concluded. Does anyone know what is the conclusion?
Now financially backed, SIERRA can well proceed with the research and participate from any collaboration GSK have in the pipe. Call it internal and external services they buy in.
GSK states re it’s Pipeline: ... For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified. Brand names are trademarks either owned by and/or licensed to GSK or associated companies.
Potnak if this were to happen it would impact negatively on Sar, to lose rights to royalties that with 737 could eventually treat 50% of cancers and also given the long wait of dead time. I personally hope this doesn’t happen but it’s a cut throat world out there. If GSK want a Tyk2 they could T/o Sar and payoff CPF which would enable a similar outcome for them with regards 737.
That simple eh! Very happy with that.
Stonking buy just got more Stonking
Well, well, the vote is YES!
https://central.virtualshareholdermeeting.com/vsm/web?pvskey=SRRA2022SM
Is there a link you can please share - apologies if you've already done that.
Bill.
Just in case anyone was wondering, you can log in to the Sierra meeting as a guest, you don't have to be a shareholder.
In the here and now I don't agree, SOG. Its just not what I'm seeing from the CPF agreement - within the license agreement there are 'NO' (like zero) oncology indication on licensing provisions. Only non-oncology indication provisions.
'If' GSK want to on license, they are going to have to first sort something out with the CPF by way of a formal agreement. In that case, YES, I agree that being GSK will give them some helpful muscle in those discussions. But, the black and white of the agreement means they are going to have to get the CPF on board before being able to do any oncology indication on licensing.
Bill.
BB. Sierra can on license to Zentalis. In this matter GSK will have a fair degree of sway if that is what they want. Sierra have ownership of the license for 737.
Aye - got it now Bill. There was a short time lag in my reading and understanding :)